Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA1 | P02708 | 1/20 | 0.50 |
| ▸ | CHRNG | P07510 | 1/20 | 0.50 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | CHRND | Q07001 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8796442 | 0.98 | CHRNA1 (0.49) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL1163376 | 0.83 | HPGD (0.56) | PARP1SMN1; SMN2ALDH1A1MAPTTSHR | |
| SCHEMBL27581493 | 0.83 | HTT (0.53) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL588574 | 0.81 | CHRNA1 (0.51) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL1806409 | 0.81 | PARP1 (0.50) | PARP1SMN1; SMN2MAPK1LCKBRD4 | |
| SCHEMBL141936 | 0.81 | TSHR (0.52) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL29784872 | 0.81 | CHRNA1 (0.51) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL1002832 | 0.80 | PRSS1 (0.61) | PARP1SMN1; SMN2MAPK1LCKALDH1A1 | |
| SCHEMBL29503140 | 0.80 | PRSS1 (0.61) | PARP1SMN1; SMN2MAPK1LCKALDH1A1 | |
| SCHEMBL27557037 | 0.80 | PARP1 (0.54) | PARP1SMN1; SMN2MAPK1LCKBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115010621-B | Synthesis method of 4-bromo-3-methylbenzonitrile | 山东百启生物医药有限公司 | 2023-11-03 | — | — | CN | claimed |
| CN-115010621-A | Synthetic method of 4-bromo-3-methylbenzonitrile | 山东百启生物医药有限公司 | 2022-09-06 | — | — | CN | claimed |
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | claimed |
| US-20100256132-A1 | IL-12 MODULATORY COMPOUNDS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2010-10-07 | — | — | US | claimed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | claimed |
| JP-2007523865-A | — | — | 2007-08-23 | — | — | JP | claimed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| US-7129235-B2 | Amides useful for treating pain | ABBOTT LABORATORIES (US) | 2006-10-31 | — | — | US | claimed |
| US-20060223996-A1 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2006-10-05 | — | — | US | claimed |
| EP-1646621-A2 | NOVEL AZAHETEROCYCLIC AMIDES USEFUL FOR TREATING PAIN | Abbott Laboratories (US) | 2006-04-19 | — | — | EP | claimed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | claimed |
| US-20050080095-A1 | administering a therapeuitcally effective amount of 3'-(trifluoromethyl)-N-{4-[(trifluoromethyl)sulfonyl]phenyl}-3,6-dihydro-2H-1,2'-bipyridine-4-carboxamide; antagonists of vanilloid receptor subtype I | ABBVIE INC. | 2005-04-14 | — | — | US | claimed |
| WO-2005007642-A2 | NOVEL AZAHETEROCYCLIC AMIDES USEFUL FOR TREATING PAIN | ABBOTT LABORATORIES (US) | 2005-01-27 | — | — | WO | claimed |
| EP-4565562-B1 | PYRROLIDINE-2-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | NXERA PHARMA UK LTD (GB) | 2026-05-27 | — | — | EP | disclosed |
| US-20260042745-A1 | PYRROLIDINE-2-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | NXERA PHARMA UK LIMITED (GB) | 2026-02-12 | — | — | US | disclosed |
| US-12492174-B2 | Morpholine-3-carboxamide derivatives as prostaglandin E2 receptor 4 (EP4) agonists for the treatment of gastrointestinal and pulmonary diseases | NXERA PHARMA UK LIMITED (GB) | 2025-12-09 | — | — | US | disclosed |
| EP-0733048-A1 | HETEROCYCLIC BIPHENYLYLAMIDES USEFUL AS 5HT1D ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1996-09-25 | — | — | EP | disclosed |
| WO-1996019477-A1 | TETRACYCLIC SPIRO COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS 5HT1D RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1996-06-27 | — | — | WO | disclosed |
| EP-0702012-A1 | Substituted isoxazole sulfonamides and their use as endothelin antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-03-20 | — | — | EP | disclosed |
| WO-1995015954-A1 | HETEROCYCLIC BIPHENYLYLAMIDES USEFUL AS 5HT1D ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223996-A1 | IL-12 modulatory compounds | IL2, IL4, IFNG | CHRNA1 3781/4885CHRNG 1855/4885CHRNB1 3719/4885 |
| US-20260042745-A1 | PYRROLIDINE-2-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | PTGER4, PTGER1, PTGER2 | CHRNA1 183/4885CHRNG 210/4885CHRNB1 261/4885 |
| US-12492174-B2 | Morpholine-3-carboxamide derivatives as prostaglandin E2 receptor 4 (EP4) agonists for the treatment of gastrointestinal and pulmonary diseases | PTGER4, PTGER1, PTGER2 | CHRNA1 309/4885CHRNG 326/4885CHRNB1 451/4885 |
| US-20050080095-A1 | administering a therapeuitcally effective amount of 3'-(trifluoromethyl)-N-{4-[(trifluoromethyl)sulfonyl]phenyl}-3,6-dihydro-2H-1,2'-bipyridine-4-carboxamide; antagonists of vanilloid receptor subtype I | TRPV1, OPRL1, TRPV6 | CHRNA1 149/4885CHRNG 370/4885CHRNB1 240/4885 |
| US-20100256132-A1 | IL-12 MODULATORY COMPOUNDS | IL2, IL4, IFNG | CHRNA1 3781/4885CHRNG 1855/4885CHRNB1 3719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.